search
Back to results

Evolutionary Systems Therapy for Schizotypy (ESTS-RCT)

Primary Purpose

Schizotypal Personality Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Evolutionary Systems Therapy for Schizotypy
Cognitive Behavioral Therapy
Sponsored by
Tages Onlus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizotypal Personality Disorder focused on measuring compassion, metacognition, personality disorder, schizotypy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of Schizotypal Personality Disorder at SCID-5-AMPD Module III Age 18 or older Being capable of reading and signing the inform consent form in Italian Being capable of attending a talk therapy in Italian Exclusion Criteria: Being diagnosed with schizophrenia spectrum disorders or other psychosis disorder Being diagnosed with neurodevelopmental or neurological disorders Being diagnosed with bipolar disorder Being under any psychological or pharmacological treatment

Sites / Locations

  • Centro di Psicologia e Psicoterapia Tages Onlus - FirenzeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Cognitive Behavioral Therapy

Evolutionary Systems Therapy for Schizotypy

Arm Description

Cognitive Behavioral Therapy for Personality Disorder as manualized by Beck, Davis, Freeman and Beck in their book (2016) will be delivered to partecipants in the active control group.

Evolutionary Systems Therapy for Schizotypy as manualized by Cheli and colleagues in their trial (2023) will be delivered to partecipants in the experimental group.

Outcomes

Primary Outcome Measures

Change in general symptomatology
Change in the total score of Symptom Checklist-90-R (SCL-90-R) between two measurements

Secondary Outcome Measures

Change in metacognition
Change in total score of Metacognition Assessment Scale - Abbreviated (MAS-A) between two measurements
Change in critical beliefs about self
Change in the Hated-self scale of The Forms of Self-Criticizing/attacking and Self-reassuring Scale (FSCRS) between two measurements
Change in critical beliefs about others
Change in Socially prescribed perfectionism scale of Multidimensional Perfectionism Scale (MPS) between two measurements
Change in schizotypal traits 1
Change in Psychoticism scale of Personality Inventory for DSM-5 (PID-5) between two measurements
Change in schizotypal traits 2
Change in Detachment scale of Personality Inventory for DSM-5 (PID-5) between two measurements
Change in remission from primary diagnosis
Change in Diagnosis of Schizotypal Personality Disorders trough Structured Clinical Interview for the DSM-5 Alternative Model for Personality Disorders (SCID-5-AMPD) Module III between two measurements

Full Information

First Posted
January 17, 2023
Last Updated
July 5, 2023
Sponsor
Tages Onlus
search

1. Study Identification

Unique Protocol Identification Number
NCT05710926
Brief Title
Evolutionary Systems Therapy for Schizotypy
Acronym
ESTS-RCT
Official Title
A Confirmatory Randomized Controlled Trial Comparing Evolutionary Systems Therapy for Schizotypal Personality Disorder With Cognitive Behavioral Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 5, 2022 (Actual)
Primary Completion Date
November 1, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tages Onlus

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims at replicating existing preliminary evidence about the effectiveness of Evolutionary Systems Therapy for Schizotypy (ESTS). The present randomized controlled trial (RCT) will compare ESTS with Cognitive Behavioral Therapy (CBT) in treating Schizotypal Personality Disorder (SPD). The main questions our RCT aims to answer are: Is ESTS more effective than CBT in treating SPD? Is ESTS more feasible than CBT in treating SPD? 38 patients diagnosed with SPD will be recruited and randomly allocated to either the experimental group (i.e. ESTS) or the control group (CBT). Primary outcome will be reduction in general symptomatology, whereas secondary outcomes will be changes in target mechanisms (self-criticism and metacognition) and remission from diagnosis.
Detailed Description
A previous study suggested how ESTS (experimental group; EG) may be not inferior in respect to a combine treatment comprising of CBT and psychopharmacological treatment (control group; CG). Despite the encouraging results, it has been suggested that the presence in the CG of a mandatory pharmacological treatment would have represented a bias. Indeed, a few partecipants refused pharmacological treatment. Thus, the investigators outlined an RCT aimed at comparing the two interventions (ESTS and CBT) without any mandatory pharmacological treatment. Moreover, the investigators consider the need for a pharmacological treatment during the study as an exclusion criterion. The investigators expect to extend our knowledge about the feasbility and effectiveness of ESTS for those diagnosed with SPD:

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizotypal Personality Disorder
Keywords
compassion, metacognition, personality disorder, schizotypy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are randomly assignedon a 1:1 ratio to one of two groups in parallel for the duration of the study. Each participant will access a talk therapy lasting 6 months (24 weekly sessions).
Masking
InvestigatorOutcomes Assessor
Masking Description
An experienced first clinician will make the initial assessment without knowing the assignment to the two groups. Similarly, a second expert clinician will evaluate the participants at the end of th.e intervention without knowing the assignment to the two groups. The data will then be anonymized and a statistician will analyze them without knowing which group corresponds to which treatment
Allocation
Randomized
Enrollment
28 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cognitive Behavioral Therapy
Arm Type
Active Comparator
Arm Description
Cognitive Behavioral Therapy for Personality Disorder as manualized by Beck, Davis, Freeman and Beck in their book (2016) will be delivered to partecipants in the active control group.
Arm Title
Evolutionary Systems Therapy for Schizotypy
Arm Type
Experimental
Arm Description
Evolutionary Systems Therapy for Schizotypy as manualized by Cheli and colleagues in their trial (2023) will be delivered to partecipants in the experimental group.
Intervention Type
Behavioral
Intervention Name(s)
Evolutionary Systems Therapy for Schizotypy
Intervention Description
A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy
Intervention Description
An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
Primary Outcome Measure Information:
Title
Change in general symptomatology
Description
Change in the total score of Symptom Checklist-90-R (SCL-90-R) between two measurements
Time Frame
2 measurements: one at baseline assessment; one at final assessment
Secondary Outcome Measure Information:
Title
Change in metacognition
Description
Change in total score of Metacognition Assessment Scale - Abbreviated (MAS-A) between two measurements
Time Frame
2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Title
Change in critical beliefs about self
Description
Change in the Hated-self scale of The Forms of Self-Criticizing/attacking and Self-reassuring Scale (FSCRS) between two measurements
Time Frame
2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Title
Change in critical beliefs about others
Description
Change in Socially prescribed perfectionism scale of Multidimensional Perfectionism Scale (MPS) between two measurements
Time Frame
2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Title
Change in schizotypal traits 1
Description
Change in Psychoticism scale of Personality Inventory for DSM-5 (PID-5) between two measurements
Time Frame
2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Title
Change in schizotypal traits 2
Description
Change in Detachment scale of Personality Inventory for DSM-5 (PID-5) between two measurements
Time Frame
2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)
Title
Change in remission from primary diagnosis
Description
Change in Diagnosis of Schizotypal Personality Disorders trough Structured Clinical Interview for the DSM-5 Alternative Model for Personality Disorders (SCID-5-AMPD) Module III between two measurements
Time Frame
2 measurements: one at baseline assessment (once the intervention starts); one at final assessment (6 months after, that is after weekly scheduled 24 sessions)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of Schizotypal Personality Disorder at SCID-5-AMPD Module III Age 18 or older Being capable of reading and signing the inform consent form in Italian Being capable of attending a talk therapy in Italian Exclusion Criteria: Being diagnosed with schizophrenia spectrum disorders or other psychosis disorder Being diagnosed with neurodevelopmental or neurological disorders Being diagnosed with bipolar disorder Being under any psychological or pharmacological treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Simone Cheli, PhD
Phone
+393285642442
Email
simone.cheli@tagesonlus.org
First Name & Middle Initial & Last Name or Official Title & Degree
Marta Floridi, PsyD
Phone
+39055679037
Email
marta.floridi@tagesonlus.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Cheli, PhD
Organizational Affiliation
Tages Onlus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centro di Psicologia e Psicoterapia Tages Onlus - Firenze
City
Firenze
State/Province
FI
ZIP/Postal Code
50137
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Veronica Cavalletti
Phone
+39 055 679037
Email
veronica.cavalletti@tagesonlus.org
First Name & Middle Initial & Last Name & Degree
Marta Floridi
Email
marta.floridi@tagesonlus.org
First Name & Middle Initial & Last Name & Degree
Simone Cheli, PhD
First Name & Middle Initial & Last Name & Degree
Gil Goldzweig, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The data will be anonymized and shared through Open Science Foundation at the end of the study.
IPD Sharing Time Frame
Study protocol, SAP, and ICF will be shared before the end of February 2023.

Learn more about this trial

Evolutionary Systems Therapy for Schizotypy

We'll reach out to this number within 24 hrs